254 related articles for article (PubMed ID: 37800288)
41. Intervention on gut microbiota may change the strategy for management of colorectal cancer.
Taghinezhad-S S; Mohseni AH; Fu X
J Gastroenterol Hepatol; 2021 Jun; 36(6):1508-1517. PubMed ID: 33295040
[TBL] [Abstract][Full Text] [Related]
42. Gut microbiota modulation: a novel strategy for prevention and treatment of colorectal cancer.
Fong W; Li Q; Yu J
Oncogene; 2020 Jun; 39(26):4925-4943. PubMed ID: 32514151
[TBL] [Abstract][Full Text] [Related]
43. Human Gut Microbiome: A New Frontier in Cancer Diagnostics & Therapeutics.
Rani V; Singhal S; Sharma K; Vaid R; Aggarwal K; Bhadana R; Agarwal R; Atale N
Curr Pharm Des; 2021; 27(45):4578-4592. PubMed ID: 34620056
[TBL] [Abstract][Full Text] [Related]
44. The Microbiome as a Therapy in Pouchitis and Ulcerative Colitis.
LeBlanc JF; Segal JP; de Campos Braz LM; Hart AL
Nutrients; 2021 May; 13(6):. PubMed ID: 34071065
[TBL] [Abstract][Full Text] [Related]
45. Microbiota metabolite short chain fatty acids, GPCR, and inflammatory bowel diseases.
Sun M; Wu W; Liu Z; Cong Y
J Gastroenterol; 2017 Jan; 52(1):1-8. PubMed ID: 27448578
[TBL] [Abstract][Full Text] [Related]
46. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.
Suk KT; Kim DJ
Expert Rev Gastroenterol Hepatol; 2019 Mar; 13(3):193-204. PubMed ID: 30791767
[TBL] [Abstract][Full Text] [Related]
47. Characterisation and therapeutic manipulation of the gut microbiome in inflammatory bowel disease.
Schulberg J; De Cruz P
Intern Med J; 2016 Mar; 46(3):266-73. PubMed ID: 26968595
[TBL] [Abstract][Full Text] [Related]
48. Elucidation of Prebiotics, Probiotics, Postbiotics, and Target from Gut Microbiota to Alleviate Obesity via Network Pharmacology Study.
Oh KK; Gupta H; Min BH; Ganesan R; Sharma SP; Won SM; Jeong JJ; Lee SB; Cha MG; Kwon GH; Jeong MK; Hyun JY; Eom JA; Park HJ; Yoon SJ; Choi MR; Kim DJ; Suk KT
Cells; 2022 Sep; 11(18):. PubMed ID: 36139478
[TBL] [Abstract][Full Text] [Related]
49. The gut microbiota and inflammatory noncommunicable diseases: associations and potentials for gut microbiota therapies.
West CE; Renz H; Jenmalm MC; Kozyrskyj AL; Allen KJ; Vuillermin P; Prescott SL;
J Allergy Clin Immunol; 2015 Jan; 135(1):3-13; quiz 14. PubMed ID: 25567038
[TBL] [Abstract][Full Text] [Related]
50. The role of the microbiome for human health: from basic science to clinical applications.
Mohajeri MH; Brummer RJM; Rastall RA; Weersma RK; Harmsen HJM; Faas M; Eggersdorfer M
Eur J Nutr; 2018 May; 57(Suppl 1):1-14. PubMed ID: 29748817
[TBL] [Abstract][Full Text] [Related]
51. Gut microbiota in inflammatory bowel disease: a target for therapy not to be missed.
Larussa T; Abenavoli L; Fabiano G; Mancuso MA; Polimeni N; Dumitrascu DL; Luzza F
Minerva Gastroenterol (Torino); 2021 Dec; 67(4):357-368. PubMed ID: 35040302
[TBL] [Abstract][Full Text] [Related]
52. Pharmacomicrobiomics in Anticancer Therapies: Why the Gut Microbiota Should Be Pointed Out.
Conti G; D'Amico F; Fabbrini M; Brigidi P; Barone M; Turroni S
Genes (Basel); 2022 Dec; 14(1):. PubMed ID: 36672796
[TBL] [Abstract][Full Text] [Related]
53. Complex interactions between the microbiome and cancer immune therapy.
Schwartz DJ; Rebeck ON; Dantas G
Crit Rev Clin Lab Sci; 2019 Dec; 56(8):567-585. PubMed ID: 31526274
[TBL] [Abstract][Full Text] [Related]
54. Modulation of Gut-Brain Axis by Probiotics: A Promising Anti-depressant Approach.
Rajanala K; Kumar N; Chamallamudi MR
Curr Neuropharmacol; 2021; 19(7):990-1006. PubMed ID: 33327916
[TBL] [Abstract][Full Text] [Related]
55. The gut microbiota and gut disease.
Fehily SR; Basnayake C; Wright EK; Kamm MA
Intern Med J; 2021 Oct; 51(10):1594-1604. PubMed ID: 34664371
[TBL] [Abstract][Full Text] [Related]
56. Targeting the gut microbiota and its metabolites for type 2 diabetes mellitus.
Wu J; Yang K; Fan H; Wei M; Xiong Q
Front Endocrinol (Lausanne); 2023; 14():1114424. PubMed ID: 37229456
[TBL] [Abstract][Full Text] [Related]
57. The Species of Gut Bacteria Associated with Antitumor Immunity in Cancer Therapy.
Qi X; Liu Y; Hussein S; Choi G; Kimchi ET; Staveley-O'Carroll KF; Li G
Cells; 2022 Nov; 11(22):. PubMed ID: 36429112
[TBL] [Abstract][Full Text] [Related]
58. Modulation of the gut microbiota: a focus on treatments for irritable bowel syndrome.
Harris LA; Baffy N
Postgrad Med; 2017 Nov; 129(8):872-888. PubMed ID: 28936910
[TBL] [Abstract][Full Text] [Related]
59. Therapeutic Potential of the Gut Microbiota in the Prevention and Treatment of Sepsis.
Haak BW; Prescott HC; Wiersinga WJ
Front Immunol; 2018; 9():2042. PubMed ID: 30250472
[TBL] [Abstract][Full Text] [Related]
60. Gut microbial flora, prebiotics, and probiotics in IBD: their current usage and utility.
Scaldaferri F; Gerardi V; Lopetuso LR; Del Zompo F; Mangiola F; Boškoski I; Bruno G; Petito V; Laterza L; Cammarota G; Gaetani E; Sgambato A; Gasbarrini A
Biomed Res Int; 2013; 2013():435268. PubMed ID: 23991417
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
